volociximab
mAbexperimental
Volociximab is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin. — Wikipedia
Clinical trial activity
10 trials · 29 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00099970)
Timeline
Indications
Mechanism of action
- Integrin alpha-5/beta-1ANTAGONIST
Integrin alpha-5/beta-1 antagonist
- Fibronectin receptor alphaINHIBITOR
ITGA5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVolociximab ↗
- ChEMBLCHEMBL2108061 ↗
Also known as
- m200
- m200
- volociximab
- volociximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00782093 | Phase 1 | Oct 1, 2008 | Iveric Bio |
| NCT00666692 | Phase 1 | Apr 1, 2008 | Abbott |
| NCT00654758 | Phase 1 | Dec 1, 2007 | Abbott |
| NCT00516841 | Phase 2 | Aug 1, 2007 | Advent Health, Baylor University, Billings Clinic, Biogen, Facet Biotech, Harvard University, Indiana University, James Graham Brown Cancer Center, Johns Hopkins University, Mary Crowley Cancer Center, Memorial Health University Medical Center, Temple University, University of Alberta, University of California, Irvine, University of California, Los Angeles, University of Chicago, University of Oklahoma, University of Western Ontario, Yeshiva University |
| NCT00635193 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | AbbVie, Biogen |
| NCT00369395 | Phase 2 | Dec 1, 2006 | Abbott, Biogen |
| NCT00278187 | Phase 2 | Jul 1, 2005 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00401570 | Phase 2 | Mar 1, 2005 | AbbVie |
| NCT00100685 | Phase 2 | Jan 1, 2005 | Abbott |
| NCT00099970 | Phase 2 | Dec 1, 2004 | Palmetto Hematology Oncology, P.C., PDL BioPharma, University of Alabama, Birmingham, University of Arizona, University of California, Los Angeles, University of Pittsburgh, University of Texas at Houston |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (29)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 4 | 4 | 2 | 2005 |
| Biogen | For profit | 3 | 0 | 1 | 2006 |
| University of California, Los Angeles | Academic/Hospital | 3 | 1 | 1 | 2004 |
| AbbVie | For profit | 2 | 2 | 1 | 2005 |
| Advent Health | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Billings Clinic | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Facet Biotech | For profit | 1 | 1 | 1 | 2007 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Iveric Bio | For profit | 1 | 1 | 1 | 2008 |
| James Graham Brown Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Mary Crowley Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Memorial Health University Medical Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
| Palmetto Hematology Oncology, P.C. | Academic/Hospital | 1 | 0 | 1 | 2004 |
| PDL BioPharma | For profit | 1 | 1 | 1 | 2004 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2004 |
29 organizations
Page 1 / 2